GLP-1 Medications
Written by Dan Cripe, RN, BSN & Marcia Cripe, RN | Last Updated: September 13, 2026
GLP-1 Medications
If you're trying to understand GLP-1 medications, the hardest part may be figuring out where to start.
Ozempic and Wegovy contain the same drug but aren't interchangeable products. Mounjaro and Zepbound are another same-molecule pair. Some medications target GLP-1 alone, while tirzepatide targets GLP-1 and GIP. There are injections, daily pills, older GLP-1s, compounded versions, and now an entirely different kind of non-peptide oral GLP-1.
Then there are the questions that come after you understand the names.
Which medication produces more weight loss? Does a higher dose always work better? What happens if semaglutide barely works for you? Can you switch medications? How long does a dose stay in your body? What medications interact with GLP-1s? And who shouldn't take one at all?
This section is where we answer those questions.
You don't need to read every page in order. Start with the question that brought you here, then follow the medication or comparison that applies to you.
Start Here: Understand What These Medications Actually Do
Before comparing brand names and trial percentages, it helps to understand what GLP-1 medications are changing inside your body.
How GLP-1 Receptor Agonists Work: The Science of Incretin Mimetics
If you've wondered how one medication can affect hunger, blood sugar, food noise, digestion, and weight at the same time, start here.
You'll learn what your natural GLP-1 hormone does, why pharmaceutical GLP-1 medications last much longer, how they affect insulin and glucagon, and what happens in the brain and gastrointestinal tract after GLP-1 receptors are activated.
Start here if: You want the biology to make sense before you start comparing medications.
The Complete GLP-1 Dosing Ladder: Starter, Intermediate, and Maximum Tiers
The starting dose is not a test you have to pass, and the maximum dose is not automatically the goal.
This guide walks you through the actual escalation schedules for semaglutide and tirzepatide, why doses are increased gradually, what maintenance dosing means, and why milligrams from one medication cannot be converted directly into milligrams of another.
Start here if: You're trying to understand where your current dose fits or whether you should expect more from the next one.
Find Your Medication
Sometimes you don't need a comparison yet.
You already know the name on your prescription, or you've heard about a particular medication and want to understand exactly what it is before going any further.
Start with the medication you're taking or considering. These guides cover what the drug targets, what it's approved for, how it's dosed, what clinical trials found, common side effects, major safety considerations, and the practical questions that tend to come up once you actually start using it.
Ozempic: Semaglutide for Type 2 Diabetes
Ozempic is a once-weekly semaglutide injection approved primarily for type 2 diabetes, with additional cardiovascular and kidney-related indications for certain patients.
This guide explains how Ozempic works, its 0.25-to-2 mg dosing progression, what its clinical trials actually show about weight loss, and why Ozempic and Wegovy aren't interchangeable simply because they contain the same molecule.
Start here if: Ozempic is on your prescription—or you're trying to understand what it actually does beyond the weight-loss headlines.
Ozempic: Semaglutide for Type 2 Diabetes
Wegovy: Semaglutide for Chronic Weight Management
Wegovy is semaglutide specifically developed and approved for chronic weight management, with additional approved uses in certain populations.
Here we cover injectable and oral Wegovy, dosing and escalation, expected weight-loss ranges, cardiovascular evidence, side effects, safety considerations, and what happens when treatment is continued or stopped.
Start here if: You're taking Wegovy or considering semaglutide specifically for obesity treatment.
Wegovy: Semaglutide for Chronic Weight Management
Mounjaro: Tirzepatide for Type 2 Diabetes
Mounjaro introduced a different kind of incretin treatment by activating both GIP and GLP-1 receptors.
This guide explains how tirzepatide differs from semaglutide, Mounjaro's approved uses, its 2.5-to-15 mg dosing system, glucose and weight effects, common side effects, and how the diabetes-branded product differs from Zepbound.
Start here if: You take Mounjaro or want to understand why dual GIP/GLP-1 agonism matters.
Mounjaro: Tirzepatide for Type 2 Diabetes
Zepbound: Tirzepatide for Chronic Weight Management
Zepbound contains the same tirzepatide molecule as Mounjaro but is approved specifically for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity.
This guide walks through dosing, the SURMOUNT weight-loss evidence, side effects, maintenance dosing, what the OSA indication actually means, and the practical realities of long-term tirzepatide treatment.
Start here if: Zepbound is the medication you're taking or considering for weight management.
Zepbound: Tirzepatide for Chronic Weight Management
Rybelsus: Oral Semaglutide
Rybelsus was the medication that proved a peptide GLP-1 could be delivered as a daily tablet.
That comes with an unusual routine. This guide explains its approved uses, dosing, absorption technology, empty-stomach requirements, four-ounce water limit, 30-minute waiting period, side effects, and how Rybelsus differs from the newer Wegovy tablet.
Start here if: You take oral semaglutide or you're trying to understand why Rybelsus has such specific morning instructions.
Foundayo: Orforglipron
Foundayo represents a different generation of oral GLP-1 treatment.
Orforglipron is a non-peptide small-molecule GLP-1 receptor agonist, which means it can be taken without oral semaglutide's fasting and water restrictions. This guide covers dosing, clinical weight-loss results, side effects, approved uses, and what makes a small-molecule GLP-1 pharmacologically different from semaglutide.
Start here if: You want to understand the newest approach to once-daily oral GLP-1 treatment.
Saxenda: Daily Liraglutide for Weight Management
Before Wegovy and Zepbound, Saxenda was one of the major GLP-1 medications specifically approved for chronic weight management.
This guide explains why liraglutide requires daily rather than weekly injections, how its dosing works, what kind of weight loss was demonstrated in clinical trials, its side effects and safety considerations, and where Saxenda still fits now that newer medications are available.
Start here if: You've been prescribed Saxenda or want to understand the earlier generation of obesity-specific GLP-1 therapy.
Saxenda: Daily Liraglutide for Weight Management
Victoza: Daily Liraglutide for Type 2 Diabetes
Victoza contains the same active molecule as Saxenda—liraglutide—but the products have different approved uses and dosing.
This guide explains Victoza's role in type 2 diabetes, its cardiovascular evidence, daily dosing, weight effects, and why the same molecule can function differently as a diabetes product and an obesity product.
Start here if: You're taking Victoza or trying to understand the difference between Victoza and Saxenda.
Victoza: Daily Liraglutide for Type 2 Diabetes
Trulicity: Weekly Dulaglutide
Trulicity is a once-weekly GLP-1 receptor agonist used for type 2 diabetes and cardiovascular risk reduction in appropriate patients.
It doesn't produce the same average weight loss seen with modern obesity-dose semaglutide or tirzepatide, but weight loss isn't the only reason a GLP-1 medication may be prescribed. This guide explains dulaglutide's dosing, glucose and cardiovascular evidence, weight effects, side effects, and why clinicians still use it.
Start here if: You're taking Trulicity and wondering how it fits into today's much larger GLP-1 medication landscape.
Trulicity: Weekly Dulaglutide
Retatrutide: The Investigational Triple Agonist
Retatrutide isn't an approved medication yet, which makes this guide different from the others in this section.
It activates GIP, GLP-1, and glucagon receptors and has produced some of the largest average weight reductions reported in obesity drug trials. This guide tracks what the Phase 2 and Phase 3 trials actually show, side effects and safety signals, regulatory status, and what we still don't know before approval.
Start here if: You're hearing extraordinary claims about retatrutide and want to separate published trial evidence from what isn't clinically available yet.
Retatrutide: The Investigational Triple Agonist
Semaglutide or Tirzepatide?
This is one of the biggest decisions people encounter in modern obesity treatment.
Semaglutide and tirzepatide overlap in many ways, but they are not the same medication. Semaglutide targets GLP-1 receptors. Tirzepatide targets both GIP and GLP-1 receptors.
We have also reached the point where they have been tested directly against each other.
Semaglutide vs. Tirzepatide: Efficacy, Mechanism, and Weight Loss Differences
This is the full comparison.
We break down single versus dual incretin agonism, the head-to-head clinical trial data, gastrointestinal side effects, and what we actually know about transitioning from semaglutide to tirzepatide.
There is no made-up milligram conversion and no assumption that the medication producing the larger trial average is automatically the right medication for you.
Read this if: You're choosing between semaglutide and tirzepatide or considering moving from one to the other.
Ozempic vs. Wegovy: Same Molecule, Different Dosages and Approvals
Ozempic and Wegovy both contain semaglutide.
That doesn't make the products identical.
Their approved uses, doses, devices, insurance pathways, and treatment goals differ. This guide explains where the products overlap and where they don't—including why comparing the maximum Ozempic dose with obesity-dose Wegovy isn't as simple as comparing two numbers.
Read this if: You're confused about why the same molecule has two different brand names.
Mounjaro vs. Zepbound: Comparing Tirzepatide Brands and Approvals
Mounjaro and Zepbound contain the same active medication: tirzepatide.
Here we separate the molecule from the brand name and explain the different FDA-approved indications, dosing, maintenance options, insurance considerations, and what switching between tirzepatide brands really means.
Read this if: Someone told you Mounjaro and Zepbound are “basically the same” and you want to know exactly what that does—and doesn't—mean.
Pills vs. Injections
For a long time, choosing an effective obesity-dose GLP-1 essentially meant accepting an injection.
That is no longer true.
There are now several approaches to oral incretin treatment, and they are not simply injectable medications placed inside tablets.
Oral vs. Injectable GLP-1s: How Daily Pills Compare to Weekly Injections
Start here for the big-picture comparison.
We look at efficacy, adherence, absorption, daily versus weekly routines, and why “I'd rather take a pill” doesn't necessarily mean the pill will be easier to live with.
Read this if: Your main question is whether you want an oral or injectable GLP-1.
The Wegovy Pill: How Once-Daily Oral Semaglutide Compares to Injections
The Wegovy tablet contains semaglutide just like injectable Wegovy, but getting a peptide medication through your stomach requires very different dosing.
This guide explains the 25 mg oral formulation, its clinical weight-loss results, the strict four-ounce water and 30-minute fasting requirements, and the FDA-labeled pathway for switching between oral and injectable Wegovy.
We also explain why the 25 mg tablet cannot be compared milligram-for-milligram with the 2.4 mg injection.
Read this if: You're considering the Wegovy pill or wondering whether you can switch from the injection.
Orforglipron Explained: The First True Non-Peptide Oral GLP-1
Orforglipron takes an entirely different approach.
Instead of finding a way to get a peptide such as semaglutide through the stomach, orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist designed to be taken orally.
That difference is why it doesn't require oral semaglutide's fasting and water restrictions.
This guide explains how it works, how its absorption differs from Rybelsus and oral Wegovy, the clinical trial results, and where the FDA-approved medication now fits into the GLP-1 landscape.
Read this if: You want an oral GLP-1 without building breakfast and coffee around your medication.
What About the Older GLP-1 Medications?
Newer doesn't automatically make older medications irrelevant.
Before Wegovy and Zepbound dominated the conversation, medications including liraglutide and dulaglutide had already accumulated years of clinical experience.
Older GLP-1 Agonists: Saxenda, Victoza, and Trulicity in the Modern Era
This guide explains where the earlier GLP-1 medications still fit.
You'll see why liraglutide requires daily injections, how Saxenda compares with obesity-dose semaglutide, what Trulicity does well, and why insurance coverage, tolerability, medical history, availability, and individual response can sometimes matter more than choosing the newest medication.
Read this if: Your clinician recommended an older GLP-1 and you're wondering why.
What If Your GLP-1 Isn't Working?
Clinical trial averages can create a strange expectation: take the medication and lose approximately the amount shown in the headline.
Real bodies don't work that way.
Some people respond extraordinarily well. Some respond close to the average. Some respond slowly. And a smaller group experiences surprisingly little weight loss despite adequate treatment.
GLP-1 Non-Responders: Why Ozempic or Mounjaro Doesn't Work for Everyone—and What to Do Next
If you're taking the medication and wondering why everyone else seems to be losing more weight, start here.
We look at what researchers actually mean by inadequate response, why you shouldn't declare treatment failure during early titration, and what we know about GLP-1 receptor genetics, diabetes, medications, endocrine conditions, and differences in brain signaling.
We also look at what can happen after an inadequate semaglutide response, including switching to tirzepatide and the emerging triple-agonist data.
Read this if: You've given the medication time and the results still aren't making sense.
What Comes After Semaglutide and Tirzepatide?
The incretin field isn't finished evolving.
Researchers are already moving beyond single GLP-1 receptor agonists and dual GIP/GLP-1 medications.
Retatrutide and the Future of Triple Agonists: GLP-1, GIP, and Glucagon
Retatrutide targets three hormone receptors rather than one or two: GIP, GLP-1, and glucagon.
The clinical trial results have made it one of the most closely watched obesity medications in development, including Phase 2 data in which every participant receiving certain higher doses reached at least 5% weight loss.
But impressive trial results and an approved medication are two different things.
This guide separates what the trials have actually shown from what we still don't know, including whether retatrutide will eventually help people who respond poorly to semaglutide or tirzepatide.
Read this if: You're following the next generation of obesity medications and want the actual evidence rather than the hype.
When GLP-1 Treatment Gets More Complicated
Choosing a medication is only the beginning.
Once you're taking it, questions start appearing that don't fit neatly into “Which drug causes more weight loss?”
What happens before surgery? Can your other medications interact with it? What if you're planning a pregnancy? Does kidney disease matter? What if you have severe gastroparesis?
These guides handle those questions.
Who Should NOT Take a GLP-1: Contraindications and Black Box Warnings
Not every scary-sounding condition is an absolute contraindication, and treating all warnings as if they mean the same thing creates unnecessary confusion.
This guide separates true labeled contraindications from warnings, precautions, and situations requiring individualized clinical judgment.
We cover medullary thyroid carcinoma and MEN2, pancreatitis, pregnancy, severe gastroparesis, gallbladder disease, kidney concerns, diabetic retinopathy, and other major safety issues.
Read this if: You have a medical condition that makes you wonder whether a GLP-1 is safe for you.
GLP-1 Drug Interactions: Oral Absorption, Insulin, and Common Medications
Most GLP-1 interactions aren't as simple as “these two drugs can never be taken together.”
Sometimes the issue is delayed gastric emptying. Sometimes it's overlapping glucose lowering. Sometimes dehydration changes the risk of another medication.
This guide covers insulin, sulfonylureas, oral contraception with tirzepatide, levothyroxine, NSAIDs, narrow-therapeutic-index medications, and the special timing problems created by oral semaglutide.
Read this if: You're trying to figure out how a GLP-1 fits into the medications you already take.
GLP-1 Drug Clearance: Half-Life, Pre-Surgery Rules, and Washout Times
Skipping one weekly injection does not mean the medication immediately disappears from your body.
Here we explain semaglutide, tirzepatide, liraglutide, and dulaglutide half-lives; what “five weeks in your system” actually means; current anesthesia guidance; and why the old blanket rule to stop every weekly GLP-1 seven days before surgery is no longer the whole story.
We also cover pregnancy planning and what happens to appetite as pharmacologic GLP-1 activity fades.
Read this if: You're having surgery, planning pregnancy, stopping treatment, or simply wondering how long your medication remains active.
Compounded GLP-1s: A Different Category of Question
Compounded semaglutide and tirzepatide became part of the GLP-1 landscape during the shortages.
The shortage situation changed.
So did the rules.
Compounded Semaglutide and Tirzepatide: Regulations, Salts, and Safety
This isn't a simple “compounded is good” or “compounded is bad” article.
We explain the difference between FDA-approved medications and compounded drugs, 503A pharmacies and 503B outsourcing facilities, semaglutide base versus salt forms, how shortage resolution changed federal compounding rules, and what a certificate of analysis can—and cannot—tell you.
You'll also learn how to verify who is actually dispensing your medication and why syringe units should never be assumed to represent the same dose across different concentrations.
And What About “Natural Ozempic”?
Once GLP-1 medications became enormously popular, supplements began borrowing their language.
Berberine is the most obvious example.
Berberine vs. GLP-1s: Does “Nature's Ozempic” Actually Work?
Berberine is biologically active and has legitimate research behind some of its metabolic effects.
It is not natural semaglutide.
This guide compares what berberine actually does with GLP-1 receptor agonism, looks at the newest weight-loss evidence, explains why berberine's poor oral bioavailability matters, and addresses whether you should combine it with tirzepatide.
We also separate studied berberine doses from the much stronger claim that there is an established berberine “weight-loss dose.”
Read this if: TikTok, social media, or supplement marketing has made you wonder whether you can get GLP-1-like results without a GLP-1.
How to Use This Medication Guide
You don't need to memorize receptor pharmacology before you can make sense of your treatment.
Start with the question you actually have.
If you're choosing between medications, read the comparisons.
If you're already taking one, go to the dosing, interaction, safety, or non-response guide that matches what you're experiencing.
If you're deciding between a pill and an injection, compare the routines as carefully as you compare the trial percentages. A medication only helps if the treatment itself works in your real life.
And if something about your treatment doesn't make sense, don't assume you're missing something obvious. GLP-1 medicine has changed remarkably quickly. Some advice that was reasonable even a few years ago—about compounding, surgery, oral treatment, available medications, or which drugs have been compared directly—is already outdated.
That's why these pages don't just tell you what a medication is.
They help you understand what the evidence means for you, what decisions still require your clinician, and where the science hasn't given us a definite answer yet.
Because understanding your medication should make treatment less confusing—not give you another wall of medical terminology to decipher.